Research Article

Addition of Nimotuzumab to Standard TPF Regimen in Locally Advanced Head and Neck Cancer: A Single Institutional Study

Table 3

Adverse effect profile of induction (TPF + N) and concurrent chemoradiation (T: docetaxel; P, cisplatin; F-5 FU, N-nimotuzumab).

Adverse effectsN = 20

Nausea/vomiting
Grade I4 (20%)
Grade II6 (30%)
Grade III2 (10%)
Grade IV3 (15%)

Mucositis
Grade I8 (40%)
Grade II2 (10%)
Grade III4 (20%)
Grade IV3 (15%)

Rash
Grade I2 (10%)

Fatigue
Grade I7 (35%)
Grade II4 (20%)
Grade III1 (5%)

Diarrhea
Grade 15 (25%)
Grade II3 (15%)

Neutropenia
Grade I5 (25%)
Grade II7 (35%)
Grade III3 (15%)
Grade IV5 (25%)

Neuropathy
Grade I4 (20%)
Grade II2 (10%)
Grade III2 (10%)